search
Back to results

Comparative Study of Two Marketed Spherical Soft Contact Lenses

Primary Purpose

Refractive Error

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
enfilcon A
senofilcon A
Sponsored by
Coopervision, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Refractive Error

Eligibility Criteria

18 Years - 38 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Subjects must satisfy the following conditions prior to inclusion in the study:

  • Based on his/her knowledge, must be in good general health.
  • Be 18 to 38 years old.
  • Be able and willing to adhere to the instructions set forth in this protocol and complete all specified evaluation.
  • Read, indicate understanding of, and sign Written Informed Consent.
  • Be existing or successfully adapted users of soft contact lenses, but not currently wearing either of the study lenses being evaluated in this trial.
  • Require a visual correction in both eyes.
  • Require a prescription between +8.00D and -12.00D and have less than -0.75D of astigmatism in both eyes.
  • Achieve visual acuity of 20/25 or better in each eye with a spherical contact lens prescription.
  • Must be able to wear their lenses at least 10 working days over the next 2-weeks; > 8 hours/day assuming there are no contraindications for doing so.
  • Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: no amblyopia; no evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes); no clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings Grade 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection); no other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea [infiltrates], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology); no aphakia

Exclusion Criteria:

Any of the following will render a subject ineligible for inclusion:

  • Greater than 0.50D of refractive astigmatism in either eye.
  • Presbyopic or current monovision contact lens wear.
  • Cannot be currently wearing of either lenses (Avaira or Oasys)
  • Presence of clinically significant (grade 2-4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  • Presence of ocular or systemic disease or need of medication which might interfere with contact lens wear.
  • Slit lamp findings that would contraindicate contact lens wear such as: pathological dry eye or associated findings; pterygium, pinguecula or corneal scars within the visual axis; neovascularization > 0.75 mm in from the limbus, giant papillary conjunctivitis (GPC) worse than Grade 1; anterior uveitis or iritis (past or present), seborrheic eczema, seborrheic conjunctivitis, history of corneal ulcer or fungal infections; poor personal hygiene
  • A known history of corneal hypoesthesia (reduced corneal sensitivity).
  • Contact lens best corrected Snellen visual acuities (VA) worse than 20/30.
  • Aphakia, Keratoconus or a highly irregular cornea

To be eligible to enter the study, subjects must have ALL of the inclusion criteria and NONE of the exclusion criteria present.

Sites / Locations

  • Advanced Eyecare
  • Eric M. White, OD, Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

enfilcon A/senofilcon A

senofilcon A/enfilcon A

Arm Description

Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.

Subjects were randomized to wear senofilcon A then enfilcon A for two weeks

Outcomes

Primary Outcome Measures

Comfort - First Intervention
Comfort - on insertion and overall assessed at baseline for first intervention on a scale 0-10. 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt,
Comfort - Second Intervention
Comfort - on insertion and overall assessed at baseline for first intervention on a scale 0-10. 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt,
Comfort - First Intervention
Participant response of comfort for first intervention of study lenses assessed at 2 weeks. Comfort at insertion, comfort at end of day, comfort at 2 weeks, and overall comfort were rated on subjective response scale. (Scale 0-10, 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt).
Comfort - Second Intervention
Participant response of comfort for first intervention of study lenses assessed at 2 weeks. Comfort at insertion, comfort at end of day, comfort at 2 weeks, and overall comfort were rated on subjective response scale. (Scale 0-10, 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt).
Comfortable Wearing Time - First Intervention
Comfortable Wearing Time. (Participant response in number of hours) Obtained at 2 weeks wear for first intervention at week two visit.
Comfortable Wearing Time - Second Intervention
Comfortable Wearing Time. (Participant response in number of hours) Obtained at 2 weeks wear for second intervention at week two visit.

Secondary Outcome Measures

Full Information

First Posted
April 12, 2012
Last Updated
October 5, 2020
Sponsor
Coopervision, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01582789
Brief Title
Comparative Study of Two Marketed Spherical Soft Contact Lenses
Official Title
Clinical Evaluation of CooperVision's Avaira Spherical Daily Wear Soft Contact Lens Versus Vistakon's Oasys Spherical Daily Wear Soft Contact Lens
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
April 9, 2012 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
July 31, 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Coopervision, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to obtain objective and subjective clinical data to compare the performance of two soft contact lenses.
Detailed Description
The study will evaluate the daily wear performance of the Avaira (enfilcon A) spherical lens during two weeks of wear compared to Vistakon's Oasys (senofilcon A) spherical lens.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractive Error

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
enfilcon A/senofilcon A
Arm Type
Active Comparator
Arm Description
Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
Arm Title
senofilcon A/enfilcon A
Arm Type
Active Comparator
Arm Description
Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
Intervention Type
Device
Intervention Name(s)
enfilcon A
Intervention Description
enfilcon A daily wear soft contact lens
Intervention Type
Device
Intervention Name(s)
senofilcon A
Intervention Description
senofilcon A daily wear soft contact lens
Primary Outcome Measure Information:
Title
Comfort - First Intervention
Description
Comfort - on insertion and overall assessed at baseline for first intervention on a scale 0-10. 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt,
Time Frame
Baseline
Title
Comfort - Second Intervention
Description
Comfort - on insertion and overall assessed at baseline for first intervention on a scale 0-10. 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt,
Time Frame
Baseline
Title
Comfort - First Intervention
Description
Participant response of comfort for first intervention of study lenses assessed at 2 weeks. Comfort at insertion, comfort at end of day, comfort at 2 weeks, and overall comfort were rated on subjective response scale. (Scale 0-10, 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt).
Time Frame
2 Weeks
Title
Comfort - Second Intervention
Description
Participant response of comfort for first intervention of study lenses assessed at 2 weeks. Comfort at insertion, comfort at end of day, comfort at 2 weeks, and overall comfort were rated on subjective response scale. (Scale 0-10, 0=uncomfortable/cannot tolerate, 10=very comfortable/cannot be felt).
Time Frame
2 Weeks
Title
Comfortable Wearing Time - First Intervention
Description
Comfortable Wearing Time. (Participant response in number of hours) Obtained at 2 weeks wear for first intervention at week two visit.
Time Frame
2 Weeks
Title
Comfortable Wearing Time - Second Intervention
Description
Comfortable Wearing Time. (Participant response in number of hours) Obtained at 2 weeks wear for second intervention at week two visit.
Time Frame
2 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
38 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects must satisfy the following conditions prior to inclusion in the study: Based on his/her knowledge, must be in good general health. Be 18 to 38 years old. Be able and willing to adhere to the instructions set forth in this protocol and complete all specified evaluation. Read, indicate understanding of, and sign Written Informed Consent. Be existing or successfully adapted users of soft contact lenses, but not currently wearing either of the study lenses being evaluated in this trial. Require a visual correction in both eyes. Require a prescription between +8.00D and -12.00D and have less than -0.75D of astigmatism in both eyes. Achieve visual acuity of 20/25 or better in each eye with a spherical contact lens prescription. Must be able to wear their lenses at least 10 working days over the next 2-weeks; > 8 hours/day assuming there are no contraindications for doing so. Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: no amblyopia; no evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes); no clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings Grade 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection); no other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea [infiltrates], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology); no aphakia Exclusion Criteria: Any of the following will render a subject ineligible for inclusion: Greater than 0.50D of refractive astigmatism in either eye. Presbyopic or current monovision contact lens wear. Cannot be currently wearing of either lenses (Avaira or Oasys) Presence of clinically significant (grade 2-4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. Presence of ocular or systemic disease or need of medication which might interfere with contact lens wear. Slit lamp findings that would contraindicate contact lens wear such as: pathological dry eye or associated findings; pterygium, pinguecula or corneal scars within the visual axis; neovascularization > 0.75 mm in from the limbus, giant papillary conjunctivitis (GPC) worse than Grade 1; anterior uveitis or iritis (past or present), seborrheic eczema, seborrheic conjunctivitis, history of corneal ulcer or fungal infections; poor personal hygiene A known history of corneal hypoesthesia (reduced corneal sensitivity). Contact lens best corrected Snellen visual acuities (VA) worse than 20/30. Aphakia, Keratoconus or a highly irregular cornea To be eligible to enter the study, subjects must have ALL of the inclusion criteria and NONE of the exclusion criteria present.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Don Siegel, OD
Organizational Affiliation
Coopervision, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Advanced Eyecare
City
Pismo Beach
State/Province
California
ZIP/Postal Code
93449
Country
United States
Facility Name
Eric M. White, OD, Inc.
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Comparative Study of Two Marketed Spherical Soft Contact Lenses

We'll reach out to this number within 24 hrs